What the rules actually say.
Key FDA actions on research peptides: warning letters, compounding decisions, and committee votes. Each item links to the primary source.
Informational only. Not legal or medical advice. For guidance on your specific situation, consult a licensed attorney or clinician.
Where each peptide stands
Every peptide in the Merit Verified catalog, placed in its current FDA regulatory bucket. Tap any peptide to see its full evidence profile.
Full FDA approval for human use. Legal with a valid prescription.
In FDA-regulated clinical trials. Not yet approved for general use.
PCAC recommended 503A inclusion in July 2026. FDA has not added these to the bulks list yet. Still restricted until rulemaking finishes.
No FDA evaluation for compounding. Sold as research use only. Gray-market status.
Reviewed September 13, 2026 · Classifications sourced from FDA.gov. This page rebuilds nightly.
Status today
Most research peptides are not FDA-approved. In July 2026, PCAC recommended adding BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax to the 503A bulks list. That vote is advisory. FDA still has to finish rulemaking.
Last reviewed: September 13, 2026 · Informational only — not legal or medical advice.
Timeline
Reverse chronological.
- Upcoming
PCAC expected to take up GHK-Cu, LL-37, Dihexa, PEG-MGF, and Melanotan II
PCAC is expected to take up GHK-Cu, LL-37, Dihexa, PEG-MGF, and Melanotan II before the end of February 2027.
McDermott Will & Schulte - Enforcement
FDA sends another wave of warning letters to research-peptide storefronts
FDA posted warning letters to several online peptide sellers on August 24, 2026, treating the listings as unapproved new drugs.
FDA.gov - Rulemaking
PCAC recommends BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax for the 503A list
PCAC recommended adding BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax to the 503A bulks list. The vote is advisory. FDA still has to finish rulemaking.
FDA.gov - Enforcement
FDA sends 30 additional warning letters and names BPC-157 with GLP-1s and SARMs
FDA issued 30 more warning letters to telehealth and direct-to-consumer companies on March 3, 2026, and named BPC-157 alongside compounded GLP-1s and SARMs.
FDA.gov - Enforcement
FDA issues 50+ warning letters in a direct-to-consumer peptide crackdown
FDA sent more than 50 warning letters to companies marketing compounded peptides directly to consumers.
FDA.gov - Rulemaking
FDA places about 19 peptides on the Category 2 significant-safety-concerns list
FDA moved about 19 peptides to Category 2, citing significant safety concerns. Most research peptides, including BPC-157, were not FDA-approved for human use.
FDA.gov
Merit Verified publishes this tracker as a factual reference for researchers and buyers trying to understand the regulatory environment. It is not legal advice, medical advice, or a compliance guide.